Coming Soon in 2025
Antibody Tools That Will Redefine p53 Discovery
Tay Biosciences is preparing to launch a focused portfolio of validated, high-specificity antibody-based tools – starting with the very complex and clinically important protein: p53.
Building on the lifetime works of Sir Professor David Lane and Dr Jean-Christophe Bourdon, Tay Biosciences is a company built and run by scientists to provide the tools needed to fully decode p53 and herald a new era for drug discovery and diagnosis.
p53 is ubiquitous and well understood to play a critical role in many of humanities critical diseases such as cancers, neurodegenerative and cardiovascular diseases.
The challenge of p53
Now understood that the single p53 gene is processed to post-transcriptionally and post-translationally to create at least 16 splice variants which are then subject to further port-translational modifications.
Following synthesis four of the splice variants assemble to bind and affect the target gene with different combinations binding to different genes and/or eliciting a different response.
The prevalence of different combinations can be indicative of a variety of diseases.
To date, very few antibodies have been available to detect variants, treating p53 as a single protein. Tay Biosciences has been founded to provide the antibodies to fully understand p53 with the ambition to advance drug discovery, disease diagnostics, prognostics & personalised treatment decisions.
Greater clarity drives discovery
- 1990’s – The Hubble Space Telescope was a quantum leap for our understanding of the cosmos.
- 2020’s – The James Webb Space Telescope built on this to provide deeper understanding, new insights and fundamentally change cosmology and astrophysics
- Our antibody panel will do this for p53 – the biological pillar of creation
Image: The Pillars of Creation, part of Eagle Nebula, as imaged by Hubble (left) and James Webb (Right) space telescopes
